# Comprehensive Coagulation Management in Cardiac Surgery: Anticoagulants, Heparin Resistance, Monitoring, and Bleeding Risks: Coagulation Management in Cardiac Surgery

## TL;DR

This paper reviews strategies for managing blood clotting during heart surgery, focusing on drugs, monitoring techniques, and new technologies to reduce bleeding risks.

## Contribution

The paper highlights emerging innovations like AI-based bleeding prediction and gene therapy for personalized coagulation care.

## Key findings

- Unfractionated heparin is the standard for CPB anticoagulation despite challenges like heparin resistance.
- Viscoelastic tests like TEG and ROTEM are key for guiding coagulation therapy during surgery.
- Emerging technologies such as machine learning and gene therapy may improve personalized coagulation management.

## Abstract

Effective coagulation management is pivotal to optimizing outcomes in cardiac
surgery, influencing bleeding risk, transfusion requirements, and overall
perioperative safety. This comprehensive review examines current strategies,
limitations, and emerging innovations across anticoagulant use, coagulation
monitoring, and bleeding management. Unfractionated heparin remains the standard
for cardiopulmonary bypass (CPB) anticoagulation, owing to its rapid
reversibility, though challenges such as heparin resistance persist.
Alternatives including low molecular weight heparins, direct thrombin
inhibitors, and novel oral anticoagulants are reserved for select indications
and carry specific limitations. Perioperative coagulation monitoring is
essential; tools such as activated clotting time (ACT), anti-factor Xa assays,
and viscoelastic tests (e.g., thromboelastography [TEG] and rotational
thromboelastometry [ROTEM]) guide targeted therapy. Despite these advances,
bleeding remains common due to factors including preoperative antithrombotic
therapy, CPB-induced coagulopathy, and postoperative hemostatic deficits.
Management strategies center on prophylactic antifibrinolytics, individualized
transfusion protocols, and the judicious use of reversal agents. Emerging
frontiers including machine learning–enhanced viscoelastic algorithms, targeted
antithrombotics (e.g., factor XI inhibitors), AI-based bleeding prediction, and
gene therapy for inherited coagulopathies promise to personalize and improve
care. Continued research is warranted to validate novel therapies and refine
evidence-based protocols for coagulation management in cardiac surgery.